Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Guangdi Li; De Clercq Erik

doi:10.1016/j.antiviral.2017.02.014

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2017

Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals

Masashi Kono, Naoshi Nishida, Satoru Hagiwara, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Kosuke Minaga, Ken Kamata, Yoriaki Komeda, Toshiharu Sakurai, Mamoru Takenaka, Masahiro Takita, Norihisa Yada, Hiroshi Ida, Yasunori Minami, Kazuomi Ueshima, Tomohiro Watanabe, Masatoshi Kudo

Article2020

Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era

David Kaplan, Marina Serper

Article2014

Current race in the development of DAAs (direct-acting antivirals) against HCV

De Clercq Erik

Article2019

Efficacy and Safety of Elbasvir/Grazoprevir Combination Therapy for Chronic Hepatitis C

Masatoshi Kudo

Article2022

Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy

David Kaplan, Claire Durkin, Marina Serper